European CHMP recommends license extension foromalizumab (Xolair)

The license extension is as an add-on therapy with intranasal corticosteroids (INC) for treatment of adults (18 years and above) with severe chronic rhinosinusitis with nasal polyps, for whom therapy with INC does not provide adequate disease control.

Source:

European Medicines Agency